{
    "clinical_study": {
        "@rank": "156653", 
        "brief_summary": {
            "textblock": "Definition: Patients with bladder cancer will be participating in this study for the\n      treatment of abnormal cells in the bladder that have returned after initial treatment OR\n      have moved to a new site in the body."
        }, 
        "brief_title": "A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium", 
        "condition": "Urologic Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma, Transitional Cell", 
                "Urologic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  You must have been diagnosed with bladder    cancer that has recurred or moved to a\n             new part of the body.\n\n          -  You must have at least one tumor that can be physically measured or scanned by x-ray.\n\n          -  You may not have had previous chemotherapy (drug) treatment OR you have had surgery\n             followed by one chemotherapy treatment at least 4 months ago.\n\n        Exclusion Criteria:\n\n          -  You may not have used an experimental medicine or device within the past month.\n\n          -  Cancer that has spread to your brain.\n\n          -  If you are unwilling or unable to take folic acid or vitamin B12 supplements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "April 30, 2002", 
        "id_info": {
            "nct_id": "NCT00034593", 
            "org_study_id": "4699", 
            "secondary_id": "H3E-MC-JMEV"
        }, 
        "intervention": [
            {
                "intervention_name": "ALIMTA", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "gemcitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Pemetrexed"
            ]
        }, 
        "keyword": [
            "Bladder cancer", 
            "metastatic", 
            "transitional cell carcinoma of the urothelium"
        ], 
        "lastchanged_date": "July 18, 2006", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland"
                    }, 
                    "name": "\"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pikonlinna", 
                        "country": "Finland"
                    }, 
                    "name": "\"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Turku", 
                        "country": "Finland"
                    }, 
                    "name": "\"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux Cedex", 
                        "country": "France"
                    }, 
                    "name": "\"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille Cedex", 
                        "country": "France"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille Cedex 09", 
                        "country": "France"
                    }, 
                    "name": "\"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France"
                    }, 
                    "name": "\"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris Cedex 14", 
                        "country": "France"
                    }, 
                    "name": "\"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Homburg/Saar", 
                        "country": "Germany"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Finland", 
                "France", 
                "Germany"
            ]
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00034593"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2006"
    }, 
    "geocoordinates": {
        "\"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.\"": "48.857 2.352", 
        "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.": "49.33 7.34"
    }
}